Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179


A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus.

Castanotto D, Zhang X, Alluin J, Zhang X, Rüger J, Armstrong B, Rossi J, Riggs A, Stein CA.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5756-E5765. doi: 10.1073/pnas.1721346115. Epub 2018 Jun 4.


Characterization of Individual Human Antibodies That Bind Pertussis Toxin Stimulated by Acellular Immunization.

Acquaye-Seedah E, Reczek EE, Russell HH, DiVenere AM, Sandman SO, Collins JH, Stein CA, Whitehead TA, Maynard JA.

Infect Immun. 2018 May 22;86(6). pii: e00004-18. doi: 10.1128/IAI.00004-18. Print 2018 Jun.


Ammonium and arsenic trioxide are potent facilitators of oligonucleotide function when delivered by gymnosis.

Zhang X, Castanotto D, Liu X, Shemi A, Stein CA.

Nucleic Acids Res. 2018 Apr 20;46(7):3612-3624. doi: 10.1093/nar/gky150.


Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.

Stein CA, Levin R, Given R, Higano CS, Nemeth P, Bosch B, Chapas-Reed J, Dreicer R.

Urol Oncol. 2018 Feb;36(2):81.e9-81.e16. doi: 10.1016/j.urolonc.2017.10.018. Epub 2017 Nov 14.


Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate.

Hussaini A, Olszanski AJ, Stein CA, Bosch B, Nemeth P.

Cancer Chemother Pharmacol. 2017 Sep;80(3):479-486. doi: 10.1007/s00280-017-3360-3. Epub 2017 Jul 10.


FDA-Approved Oligonucleotide Therapies in 2017.

Stein CA, Castanotto D.

Mol Ther. 2017 May 3;25(5):1069-1075. doi: 10.1016/j.ymthe.2017.03.023. Epub 2017 Mar 31. Review.


Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice.

Stein CA.

Mol Ther. 2016 Nov;24(11):1884-1885. doi: 10.1038/mt.2016.188. No abstract available.


Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.

Castanotto D, Lin M, Kowolik C, Koch T, Hansen BR, Oerum H, Stein CA.

Mol Ther. 2016 Jun;24(6):1117-1125. doi: 10.1038/mt.2016.54. Epub 2016 Mar 10.


A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells.

Castanotto D, Lin M, Kowolik C, Wang L, Ren XQ, Soifer HS, Koch T, Hansen BR, Oerum H, Armstrong B, Wang Z, Bauer P, Rossi J, Stein CA.

Nucleic Acids Res. 2015 Oct 30;43(19):9350-61. doi: 10.1093/nar/gkv964. Epub 2015 Oct 3.


Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.

Stein CA.

Clin Genitourin Cancer. 2015 Oct;13(5):407-9. doi: 10.1016/j.clgc.2015.05.005. Epub 2015 Jun 6. No abstract available.


Antisense oligonucleotides in cancer.

Castanotto D, Stein CA.

Curr Opin Oncol. 2014 Nov;26(6):584-9. doi: 10.1097/CCO.0000000000000127. Review.


Metastatic adrenocortical carcinoma with a prolonged response to mitotane.

Pal SK, Gartrell B, Olsson CA, Stein CA.

Oncology (Williston Park). 2014 Jul;28(7):624-5, 642. No abstract available.


Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A.

Cancer Chemother Pharmacol. 2014 Jul;74(1):151-66. doi: 10.1007/s00280-014-2476-y. Epub 2014 May 16.


Targeting angiopoietin-2 signaling in cancer therapy.

Eroglu Z, Stein CA, Pal SK.

Expert Opin Investig Drugs. 2013 Jul;22(7):813-25. doi: 10.1517/13543784.2013.793306. Epub 2013 Apr 27. Review.


Enzalutamide for the treatment of prostate cancer.

Pal SK, Stein CA, Sartor O.

Expert Opin Pharmacother. 2013 Apr;14(5):679-85. doi: 10.1517/14656566.2013.775251. Epub 2013 Feb 27. Review.


Antisense 2'-Deoxy, 2'-Fluroarabino Nucleic Acids (2'F-ANAs) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids.

Souleimanian N, Deleavey GF, Soifer H, Wang S, Tiemann K, Damha MJ, Stein CA.

Mol Ther Nucleic Acids. 2012 Sep 18;1:e43. doi: 10.1038/mtna.2012.35.


Preoperative therapy for localized prostate cancer: a comprehensive overview.

Hu J, Hsu J, Bergerot PG, Yuh BE, Stein CA, Pal SK.

Maturitas. 2013 Jan;74(1):3-9. doi: 10.1016/j.maturitas.2012.10.012. Epub 2012 Nov 14. Review.


Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.

Pal SK, Yamzon J, Sun V, Carmichael C, Saikia J, Ferrell B, Frankel P, Hsu J, Twardowski P, Stein CA, Margolin K.

Clin Genitourin Cancer. 2013 Jun;11(2):121-7. doi: 10.1016/j.clgc.2012.09.007. Epub 2012 Oct 11.


Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer.

Pal SK, Stein CA.

Clin Genitourin Cancer. 2012 Dec;10(4):274-6. doi: 10.1016/j.clgc.2012.03.007. Epub 2012 May 9. No abstract available.


Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.

Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA.

J Biol Chem. 2012 Feb 3;287(6):3777-87. doi: 10.1074/jbc.M111.261933. Epub 2011 Dec 15.


Silencing of gene expression by gymnotic delivery of antisense oligonucleotides.

Soifer HS, Koch T, Lai J, Hansen B, Hoeg A, Oerum H, Stein CA.

Methods Mol Biol. 2012;815:333-46. doi: 10.1007/978-1-61779-424-7_25.


Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR.

Ann Oncol. 2012 May;23(5):1234-40. doi: 10.1093/annonc/mdr399. Epub 2011 Sep 19.


Therapeutic oligonucleotides: the road not taken.

Stein CA, Goel S.

Clin Cancer Res. 2011 Oct 15;17(20):6369-72. doi: 10.1158/1078-0432.CCR-11-2013. Epub 2011 Aug 23.


Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.

Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Høg A, Worm J, Hedtjärn M, Souleimanian N, Miller P, Soifer HS, Castanotto D, Benimetskaya L, Ørum H, Koch T.

Nucleic Acids Res. 2010 Jan;38(1):e3. doi: 10.1093/nar/gkp841. Epub 2009 Oct 23.


LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).

Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AM.

Eur J Cancer. 2009 Jul;45(10):1807-14. doi: 10.1016/j.ejca.2009.04.016. Epub 2009 May 4.


G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis.

Stein CA, Wu S, Voskresenskiy AM, Zhou JF, Shin J, Miller P, Souleimanian N, Benimetskaya L.

Clin Cancer Res. 2009 Apr 15;15(8):2797-807. doi: 10.1158/1078-0432.CCR-08-2610. Epub 2009 Apr 7.


Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease.

Benimetskaya L, Wu S, Voskresenskiy AM, Echart C, Zhou JF, Shin J, Iacobelli M, Richardson P, Ayyanar K, Stein CA.

Blood. 2008 Nov 15;112(10):4343-52. doi: 10.1182/blood-2008-04-149682. Epub 2008 Aug 18.


Specific VDAC inhibitors: phosphorothioate oligonucleotides.

Stein CA, Colombini M.

J Bioenerg Biomembr. 2008 Jun;40(3):157-62. doi: 10.1007/s10863-008-9139-9. Review.


Antisense oligonucleotides in cancer: recent advances.

Lebedeva IV, Stein CA.

BioDrugs. 2000 Mar;13(3):195-216.


Genasense: it ain't over till the fat lady sings.

Stein CA.

Oligonucleotides. 2007 Winter;17(4):345-8. No abstract available.


The Genasense 'learning curve'.

Stein CA.

Nat Biotechnol. 2007 Sep;25(9):972-3; author reply 973. No abstract available.


Phosphorothioate oligonucleotides block the VDAC channel.

Tan W, Loke YH, Stein CA, Miller P, Colombini M.

Biophys J. 2007 Aug 15;93(4):1184-91. Epub 2007 May 4.


Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.

Zhao H, Peng P, Longley C, Zhang Y, Borowski V, Mehlig M, Reddy P, Xia J, Borchard G, Lipman J, Benimetskaya L, Stein CA.

J Control Release. 2007 Jun 4;119(2):143-52. Epub 2006 Dec 29.


Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency.

Lai JC, Brown BD, Voskresenskiy AM, Vonhoff S, Klussman S, Tan W, Colombini M, Weeratna R, Miller P, Benimetskaya L, Stein CA.

Mol Ther. 2007 Feb;15(2):270-8.


Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.

Stein CA, Goel S, Ghavamian R.

Invest New Drugs. 2007 Jun;25(3):277-8. Epub 2007 Jan 11. No abstract available.


Phosphorothioate oligonucleotides reduce mitochondrial outer membrane permeability to ADP.

Tan W, Lai JC, Miller P, Stein CA, Colombini M.

Am J Physiol Cell Physiol. 2007 Apr;292(4):C1388-97. Epub 2006 Nov 29.


Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.

Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, Lai J, Brown BD, Popova N, Miller P, McMicken H, Chen Y, Stein CA.

Clin Cancer Res. 2006 Aug 15;12(16):4940-8.


Does "stubbornness" have a role in pediatric constipation?

Burket RC, Cox DJ, Tam AP, Ritterband L, Borowitz S, Sutphen J, Stein CA, Kovatchev B.

J Dev Behav Pediatr. 2006 Apr;27(2):106-11.


A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC.

Lai JC, Tan W, Benimetskaya L, Miller P, Colombini M, Stein CA.

Proc Natl Acad Sci U S A. 2006 May 9;103(19):7494-9. Epub 2006 Apr 28.


G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.

Gekeler V, Gimmnich P, Hofmann HP, Grebe C, Römmele M, Leja A, Baudler M, Benimetskaya L, Gonser B, Pieles U, Maier T, Wagner T, Sanders K, Beck JF, Hanauer G, Stein CA.

Oligonucleotides. 2006 Spring;16(1):83-93.


Induction of apoptosis by G3139 in melanoma cells.

Benimetskaya L, Lai JC, Khvorova A, Wu S, Miller P, Stein CA.

Ann N Y Acad Sci. 2005 Nov;1058:235-45. Review.


Antisense strategies for oncogene inactivation.

Stein CA, Benimetskaya L, Mani S.

Semin Oncol. 2005 Dec;32(6):563-72. Review.


518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.

Benimetskaya L, Miller P, Stein CA.

Oligonucleotides. 2005 Fall;15(3):206-14.


Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature.

Anderson EM, Miller P, Ilsley D, Marshall W, Khvorova A, Stein CA, Benimetskaya L.

Cancer Gene Ther. 2006 Apr;13(4):406-14.


A critical assessment of the potential of short interfering RNA therapeutics.

Stein CA, Rossi JJ.

Drug Discov Today Technol. 2005 Spring;2(1):27-31. doi: 10.1016/j.ddtec.2005.05.013.


Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.

Lai JC, Benimetskaya L, Khvorova A, Wu S, Hua E, Miller P, Stein CA.

Mol Cancer Ther. 2005 Feb;4(2):305-15. Erratum in: Mol Cancer Ther. 2005 May;4(5):864.


Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.

Benimetskaya L, Lai JC, Khvorova A, Wu S, Hua E, Miller P, Zhang LM, Stein CA.

Clin Cancer Res. 2004 Dec 15;10(24):8371-9.


Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).

Raffo A, Lai JC, Stein CA, Miller P, Scaringe S, Khvorova A, Benimetskaya L.

Clin Cancer Res. 2004 May 1;10(9):3195-206.

Supplemental Content

Loading ...
Support Center